HALO - Halozyme Therapeutics, Inc. Announces Pricing of Upsized Private Offering of $1.3 Billion of Convertible Senior Notes due 2033
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.